Recently, Nayak et al. elucidatedcrystal structures of VHL/753b/BCL-xL and BCL-2, shedding light ontheir interactions.134 DT2216 is alreadyin clinical trials (T cell lymphomas) as the unique PROTAC degradertargeting BCL-xL. This evidence concerns the gene BCL2L1 and T-cell non-Hodgkin lymphoma.